WO2013123840A1 - 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 - Google Patents
抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 Download PDFInfo
- Publication number
- WO2013123840A1 WO2013123840A1 PCT/CN2013/070919 CN2013070919W WO2013123840A1 WO 2013123840 A1 WO2013123840 A1 WO 2013123840A1 CN 2013070919 W CN2013070919 W CN 2013070919W WO 2013123840 A1 WO2013123840 A1 WO 2013123840A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- cancer
- pharmaceutically acceptable
- acceptable salt
- mmol
- Prior art date
Links
- BYXARMLQXQVYIK-UHFFFAOYSA-N CCc(nc1)cc2c1C(c(cccc1)c1Cl)=Nc1c(C)[nH]nc1N2 Chemical compound CCc(nc1)cc2c1C(c(cccc1)c1Cl)=Nc1c(C)[nH]nc1N2 BYXARMLQXQVYIK-UHFFFAOYSA-N 0.000 description 1
- PLMPPXLEOFIZIA-UHFFFAOYSA-N Cc(nc1)cc(N2)c1C(c1ccccc1Cl)=NCC2=O Chemical compound Cc(nc1)cc(N2)c1C(c1ccccc1Cl)=NCC2=O PLMPPXLEOFIZIA-UHFFFAOYSA-N 0.000 description 1
- IPOIYZVLGSCAOG-UHFFFAOYSA-N Cc(nc1)cc(N2)c1C(c1ccccc1Cl)=NCC2=S Chemical compound Cc(nc1)cc(N2)c1C(c1ccccc1Cl)=NCC2=S IPOIYZVLGSCAOG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Compound 1-2 is named: 9 - (2-chlorophenyl)-6-ethyl-1-methyl-2-, 4-dihydro-2, 3, 4, 7, 10-pentaza-benzo [f]Made.
- the compound (I) of the present invention can be produced by the following method:
- the compounds of the invention all have excellent antitumor activity, IC 5 .
- the value is between 0. 03-12. 6.
- the compounds of the invention are useful in the preparation of a medicament for the treatment of neoplastic diseases.
- the following are pharmacodynamic tests and results of some of the compounds of the present invention.
- the structural formulas of the compounds 1-1 and 1-3 are shown in the examples.
- Table 2 The tumor inhibition rate of each group of nude mice after drug treatment
- Cyclophosphamide group 8 100 mg/kg 39.5 0.0395
- Table 3 The tumor inhibition rate of each group of nude mice after drug treatment
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES13751374.3T ES2617965T3 (es) | 2012-02-24 | 2013-01-24 | Derivado de aza-benzo [f] azuleno antitumoral, método para su preparación, y su uso |
US14/380,596 US9382249B2 (en) | 2012-02-24 | 2013-01-24 | Antitumor aza-benzo [f] azulen derivative, method for preparing same, and use thereof |
JP2014557981A JP5851053B2 (ja) | 2012-02-24 | 2013-01-24 | 抗腫瘍性アザベンゾ[f]アズレン誘導体およびその製造方法 |
EP13751374.3A EP2818171B1 (en) | 2012-02-24 | 2013-01-24 | Antitumor aza-benzo[f]azulen derivative, method for preparing same, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210043316.X | 2012-02-24 | ||
CN201210043316.XA CN102603743B (zh) | 2012-02-24 | 2012-02-24 | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013123840A1 true WO2013123840A1 (zh) | 2013-08-29 |
Family
ID=46521573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/070919 WO2013123840A1 (zh) | 2012-02-24 | 2013-01-24 | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9382249B2 (zh) |
EP (1) | EP2818171B1 (zh) |
JP (1) | JP5851053B2 (zh) |
CN (1) | CN102603743B (zh) |
ES (1) | ES2617965T3 (zh) |
WO (1) | WO2013123840A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102603743B (zh) | 2012-02-24 | 2014-05-28 | 南京天易生物科技有限公司 | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 |
EP3447056A4 (en) * | 2016-12-13 | 2019-09-18 | Nanjing Transthera Biosciences Co. Ltd. | MULTI-CHINE OXYGEN COMPOUND, CRYSTAL FORM AND USE THEREOF |
CN109020980B (zh) * | 2017-06-09 | 2020-11-20 | 华东师范大学 | 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物 |
US10611857B2 (en) | 2017-08-02 | 2020-04-07 | Exxonmobil Chemical Patents Inc. | Bisphenolate transition metal complexes, production and use thereof |
BR112022016618A2 (pt) * | 2020-02-24 | 2022-11-16 | Transthera Sciences Nanjing Inc | Nova forma de utilização de inibidor de multiquinase |
EP4148054A1 (en) * | 2020-05-08 | 2023-03-15 | Transthera Sciences (Nanjing), Inc. | Synthesis method for anti-tumor compound and intermediate thereof |
CN112939974B (zh) * | 2021-03-11 | 2023-10-20 | 中山大学 | 一种氮杂苯并薁衍生物的制备方法 |
WO2022206758A1 (zh) * | 2021-03-29 | 2022-10-06 | 药捷安康(南京)科技股份有限公司 | 多激酶抑制剂的联合应用 |
WO2022237765A1 (zh) * | 2021-05-10 | 2022-11-17 | 药捷安康(南京)科技股份有限公司 | 多激酶抑制剂的药物组合物及其用途 |
CN116236489A (zh) * | 2021-12-07 | 2023-06-09 | 药捷安康(南京)科技股份有限公司 | 激酶抑制剂的新用途 |
CN114957081B (zh) * | 2022-05-27 | 2024-04-05 | 中国科学院上海有机化学研究所 | 薁类化合物、其中间体、其制备方法及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1227555A (zh) * | 1996-06-12 | 1999-09-01 | 日本烟草产业株式会社 | 细胞因子生成抑制剂、三氮䓬化合物及其中间体 |
CN102603743A (zh) * | 2012-02-24 | 2012-07-25 | 南京天易生物科技有限公司 | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221907B1 (en) * | 1996-03-20 | 2001-04-24 | Hoechst Marion Roussel | Tricyclic compounds having activity specific for integrins, particularly alphanubeta3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same |
US6440959B1 (en) * | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
DE602005007623D1 (de) * | 2004-10-13 | 2008-07-31 | Hoffmann La Roche | Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine |
AU2006301292A1 (en) * | 2005-10-14 | 2007-04-19 | F. Hoffmann-La Roche Ag | Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo (3, 4.-b) (1, 4) benzodiazepine |
NZ599938A (en) * | 2009-12-01 | 2014-08-29 | Abbvie Inc | Novel tricyclic compounds |
-
2012
- 2012-02-24 CN CN201210043316.XA patent/CN102603743B/zh active Active
-
2013
- 2013-01-24 US US14/380,596 patent/US9382249B2/en not_active Expired - Fee Related
- 2013-01-24 ES ES13751374.3T patent/ES2617965T3/es active Active
- 2013-01-24 EP EP13751374.3A patent/EP2818171B1/en not_active Not-in-force
- 2013-01-24 WO PCT/CN2013/070919 patent/WO2013123840A1/zh active Application Filing
- 2013-01-24 JP JP2014557981A patent/JP5851053B2/ja not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1227555A (zh) * | 1996-06-12 | 1999-09-01 | 日本烟草产业株式会社 | 细胞因子生成抑制剂、三氮䓬化合物及其中间体 |
CN102603743A (zh) * | 2012-02-24 | 2012-07-25 | 南京天易生物科技有限公司 | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 |
Also Published As
Publication number | Publication date |
---|---|
US9382249B2 (en) | 2016-07-05 |
JP2015508083A (ja) | 2015-03-16 |
JP5851053B2 (ja) | 2016-02-03 |
CN102603743B (zh) | 2014-05-28 |
EP2818171A1 (en) | 2014-12-31 |
CN102603743A (zh) | 2012-07-25 |
ES2617965T3 (es) | 2017-06-20 |
EP2818171B1 (en) | 2016-12-28 |
EP2818171A4 (en) | 2015-09-02 |
US20150011536A1 (en) | 2015-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013123840A1 (zh) | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 | |
CN109422726B (zh) | CD47/SIRPα的阻断剂及其应用 | |
CA2736097C (en) | Carbazole compounds for inhibition of nf-kb activity | |
BR112017009012B1 (pt) | Derivados de anel benzo de seis membros como inibidor de dpp-4 e uso dos mesmos | |
WO2018149231A1 (zh) | 7H-吡咯并[2,3-d]嘧啶衍生物及抗肿瘤的应用 | |
WO2013178021A1 (zh) | 吡咯并[2,1—f][1,2,4]三嗪衍生物及其抗肿瘤用途 | |
CN111704646B (zh) | 甾体类化合物及其制备方法和用途 | |
KR20240041980A (ko) | 벤조[b]셀레노펜 STING 조절제, 이의 제조 방법 및 용도 | |
JPS6225670B2 (zh) | ||
WO2014008838A1 (zh) | 芳基取代甲基连接的双吲哚乙酸衍生物及其制备方法和应用 | |
CN110066281B (zh) | 多靶点抗肿瘤活性的吴茱萸碱衍生物及其制备方法与应用 | |
WO2013107428A1 (zh) | 7-位取代的汉防己乙素衍生物、及其制备方法和应用 | |
JPH03505204A (ja) | 3環式3―オキソ―プロパンニトリル誘導体およびその調製方法 | |
CN110467601B (zh) | 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用 | |
CN107739381B (zh) | 莪术醇衍生物及其在制备抗肿瘤药物中的应用 | |
US9499552B2 (en) | Pyrazolo[1,5-A]pyrimidine derivative and use of anti-tumor thereof | |
CN110604732B (zh) | 一种莪术醇衍生物在制备治疗结直肠癌药物中的应用 | |
JP7329052B2 (ja) | フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用 | |
TWI419894B (zh) | 4-苯胺基呋喃[2,3-b]喹啉衍生物,其製備方法以及包含有此等衍生物的藥學組成物 | |
JP2023545151A (ja) | アミノコンブレタスタチン誘導体及びその応用 | |
WO2021249558A1 (zh) | 作为rsk抑制剂的蝶啶酮衍生物及其应用 | |
CN108947904B (zh) | 一种含有七元内酰胺环的化合物及其应用 | |
CN113831346B (zh) | 多靶点抗肿瘤小分子及其衍生物、制法、药物组合物和应用 | |
US8952033B2 (en) | 4-anilinofuro[2,3-b]quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | |
CN109535060B (zh) | 一种刺猬通路抑制剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13751374 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014557981 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14380596 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013751374 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013751374 Country of ref document: EP |